[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637618":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":11,"centralContacts":29,"locations":37,"responsibleParty":100,"collaborators":11,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":104,"sex":110,"minAge":111,"maxAge":11,"enrollmentInfo":112,"targetDuration":11,"studyType":115,"phases":116,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Eyconis INC.","OTHER",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"EYC-0305 Dose Level 1","EXPERIMENTAL",null,[13],"Biological: EYC-0305",{"label":15,"type":10,"description":11,"interventionNames":16},"EYC-0305 Dose Level 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"EYC-0305 Dose Level 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"EYC-0305 Dose Level 4",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"BIOLOGICAL","EYC-0305","Extended-delivery anti-VEGF",[9,15,18,21],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Kim Reed, OD, FAAO","CONTACT","1-866-392-6647","info@eyconis.com",{"name":36,"role":32,"phone":33,"phoneExt":11,"email":34},"Karen Chu, MS",[38,52,62,72,82,91],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":11},"Beverly Hills, CA","RECRUITING","Beverly Hills","California","90211","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-118.40036,34.07362,{"lat":50,"lon":49},{"facility":53,"status":40,"city":54,"state":55,"zip":56,"country":44,"countryCode":45,"cosmosGeoPoint":57,"geoPoint":61,"contacts":11},"Wake Forest, NC","Wake Forest","North Carolina","27587",{"type":47,"coordinates":58},[59,60],-78.50972,35.97987,{"lat":60,"lon":59},{"facility":63,"status":40,"city":64,"state":65,"zip":66,"country":44,"countryCode":45,"cosmosGeoPoint":67,"geoPoint":71,"contacts":11},"Erie, PA","Erie","Pennsylvania","16505",{"type":47,"coordinates":68},[69,70],-80.08506,42.12922,{"lat":70,"lon":69},{"facility":73,"status":40,"city":74,"state":75,"zip":76,"country":44,"countryCode":45,"cosmosGeoPoint":77,"geoPoint":81,"contacts":11},"Bellaire, TX","Bellaire","Texas","77401",{"type":47,"coordinates":78},[79,80],-95.45883,29.70579,{"lat":80,"lon":79},{"facility":83,"status":40,"city":84,"state":75,"zip":85,"country":44,"countryCode":45,"cosmosGeoPoint":86,"geoPoint":90,"contacts":11},"McAllen, TX","McAllen","78503",{"type":47,"coordinates":87},[88,89],-98.23001,26.20341,{"lat":89,"lon":88},{"facility":92,"status":40,"city":93,"state":75,"zip":94,"country":44,"countryCode":45,"cosmosGeoPoint":95,"geoPoint":99,"contacts":11},"The Woodlands, TX","The Woodlands","77384",{"type":47,"coordinates":96},[97,98],-95.48938,30.15799,{"lat":98,"lon":97},{"type":101,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100637618","phase-1-phase-1b2a-study-of-eyc-0305-in-patients-with-neovascular-age-related-macular-degeneration-100637618",false,"NCT07587515","Phase 1b\u002F2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration","Open-Label, Multiple Ascending Dose Phase 1b\u002F2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration","OVERTURE","Inclusion Criteria:\n\n* Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria\n* Willing and able to comply with clinic visits and study-related procedures\n* Provide signed informed consent\n\nExclusion Criteria:\n\n* Known hypersensitivity or known allergy that would preclude study drug administration\n* Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access\n* Uncontrolled diabetes mellitus\n* History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit\n* Renal failure, dialysis, or history of renal transplant\n* Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion\n* Pregnant or breastfeeding women","ALL","50 Years",{"count":113,"type":114},30,"ESTIMATED","INTERVENTIONAL",[117,118],"PHASE1","PHASE2","This Phase 1b\u002F2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.",[121],"Neovascular (Wet) Age-Related Macular Degeneration",[26,123,124,125,126,127,128],"TransCon aVEGF","wet AMD","neovascular AMD","treatment naive","Eyconis","anti-VEGF","2026-07-06",{"date":131,"type":132},"2026-07-07","ACTUAL",{"date":134,"type":132},"2026-05-19",{"date":136,"type":114},"2028-05",{"name":5,"class":6},6]